FLT3 and acute myeloid leukemia: Recently, this paradigm was advanced by evidence that arsenic trioxide (ATO) downregulates stromal CYP26B1, thereby restoring retinoid signaling within the niche and re-sensitizing FLT3-mutant AML to gilteritinib.